# Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

> **NCT02706392** · PHASE1 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 21 (actual)

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Mantle Cell Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Stage III Lung Non-Small Cell Cancer AJCC v7
- Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Stage IV Lung Non-Small Cell Cancer AJCC v7
- Unresectable Lung Non-Small Cell Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** ROR1 CAR-specific Autologous T-Lymphocytes

## Key facts

- **NCT ID:** NCT02706392
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-16
- **Primary completion:** 2021-05-17
- **Final completion:** 2021-09-28
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Terminated due to slow accruals.
- **Last updated:** 2022-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02706392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02706392, "Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02706392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*